First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms.

Cancers (Basel) · 2025 · PMC12468345 · PMID 41008812

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In one study, a DNA microanalysis of samples from adult AML patients showed a trend for high levels of PRAME mRNA to correlate with improved overall survival (OS) [ 8 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.